Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients.

Gianni M, Bosch J, Pogue J, Probstfield J, Dagenais G, Yusuf S, Lonn E.

Eur Heart J. 2007 Jun;28(11):1382-8. Epub 2007 Mar 29.

PMID:
17395677
2.

The HOPE Study (Heart Outcomes Prevention Evaluation).

Sleight P.

J Renin Angiotensin Aldosterone Syst. 2000 Mar;1(1):18-20. Review.

PMID:
11967789
3.
4.

Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients.

Anderson VR, Perry CM, Robinson DM.

Am J Cardiovasc Drugs. 2006;6(6):417-32. Review.

PMID:
17192135
5.

Ramipril: a review of its use in the prevention of cardiovascular outcomes.

Warner GT, Perry CM.

Drugs. 2002;62(9):1381-405. Review.

PMID:
12076194
6.

Spotlight on ramipril in the prevention of cardiovascular outcomes.

Warner GT, Perry CM.

Am J Cardiovasc Drugs. 2003;3(2):113-6. Review.

PMID:
14727938
7.

What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE.

Heinig RE.

Diabetes Obes Metab. 2002 Jan;4 Suppl 1:S19-25. Review.

PMID:
11843951
8.
9.

Ramipril in the treatment of vascular diseases.

Rokoss MJ, Teo KK.

Expert Opin Pharmacother. 2005 Sep;6(11):1911-9. Review.

PMID:
16144510
11.

What is the relevance of the HOPE study in general practice?

Kennedy J, Mogensen CE, Ball SG, Castaigne AD, Commerford PJ, Distiller L, Fisher BM, Gonzalez-Jaunatey J, Nosadini R, Novials A, Ostergren J, Palma-Gámiz J, Perrone-Filardi P, Schipperheijn JJ, Senges J, Trevisan R.

Int J Clin Pract. 2001 Sep;55(7):449-57. Review.

PMID:
11594254
13.

Ramipril.

Smith WH, Ball SG.

Int J Clin Pract. 2000 May;54(4):255-60. Review.

PMID:
10912316
14.

RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.

Werner C, Baumhäkel M, Teo KK, Schmieder R, Mann J, Unger T, Yusuf S, Böhm M.

Clin Res Cardiol. 2008 Jul;97(7):418-31. doi: 10.1007/s00392-008-0668-3. Epub 2008 May 3. Review.

PMID:
18454336
15.

Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension.

Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN.

Ann Intern Med. 2008 Jan 1;148(1):16-29. Epub 2007 Nov 5. Review.

PMID:
17984484
16.

HOPE in PROGRESS--a tale of two trials: blood pressure reduction or drug mechanism?

Sander GE, Giles TD.

Am J Geriatr Cardiol. 2002 Sep-Oct;11(5):332-3. Review. No abstract available.

PMID:
12214175
17.

Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.

Brugts JJ, Ferrari R, Simoons ML.

Expert Rev Cardiovasc Ther. 2009 Apr;7(4):345-60. doi: 10.1586/erc.09.2. Review. Erratum in: Expert Rev Cardiovasc Ther. 2009 Jun;7(6):722.

PMID:
19379059
18.

Do ACE inhibitors all provide the same outcomes benefits in high-risk cardiovascular patients?

Lala A, McLaughlin MA.

Curr Hypertens Rep. 2008 Aug;10(4):286-92. Review.

PMID:
18625157
19.

Blocking the renin-angiotensin system: dual- versus mono-therapy.

Ravandi A, Teo KK.

Expert Rev Cardiovasc Ther. 2009 Jun;7(6):667-74. doi: 10.1586/erc.09.47. Review.

PMID:
19505282
20.

Should the results of the HOPE study affect nephrological practice? For the HOPE investigators.

Mann JF.

Nephrol Dial Transplant. 2000 Apr;15(4):453-4. Review. No abstract available.

PMID:
10727536

Supplemental Content

Support Center